Date: 2016-11-04
Type of information: Nomination
Compound:
Company: Advantagene (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 4, 2016, Advantagene announced that Daniel Giroux has joined the company as Vice President, Manufacturing. Mr. Giroux will be primarily responsible for the clinical and commercial production of the viral vector aglatimagene besadenovec (a.k.a. AdV-tk) currently undergoing clinical studies in localized prostate cancer, glioblastoma, pediatric glioma, pancreas and lung cancers. Mr. Giroux brings over 25 years of professional experience in bioprocess development, biopharmaceutical manufacturing and bio-processing equipment design and manufacturing to Advantagene. He is among the country’s thought leaders in the manufacture of viral vectors, with particular expertise in adenovirus production and analytical methods, having worked for 11 years at Canji, the gene therapy arm of Schering–Plough Corporation. At Canji he was instrumental in quantifying molecular diffusion in the adenovirus infection process and for the production of purified adenovirus vectors for clinical studies under a California FDB license. More recently, Mr. Giroux was Vice President of Research and Development at PBS Biotech, a manufacturer of single-use bioreactors, where he oversaw the product development of a scalable line of single use bioreactors. Mr. Giroux holds a B.Sc. in Biochemistry and a B.Sc.A in Chemical Engineering, both from the University of Ottawa.
Financial terms:
Latest news:
